These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 15905968)

  • 1. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Always look at the bright side of drugs?
    Nygren P
    Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
    [No Abstract]   [Full Text] [Related]  

  • 8. [Standard chemotherapy for colonic neoplasms].
    Hyodo I
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):283-8. PubMed ID: 17370594
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
    Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
    Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    Walter H; Thomas AL
    Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
    [No Abstract]   [Full Text] [Related]  

  • 12. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 13. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
    Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C; George T; Yothers G
    J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
    [No Abstract]   [Full Text] [Related]  

  • 16. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-line treatment of patients with metastatic colorectal cancer.
    Rougier P; Lepere C
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S48-54. PubMed ID: 16399432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Giantonio BJ; Catalano PJ; Meropol NJ; O'Dwyer PJ; Mitchell EP; Alberts SR; Schwartz MA; Benson AB;
    J Clin Oncol; 2007 Apr; 25(12):1539-44. PubMed ID: 17442997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 20. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
    Klautke G; Fietkau R
    Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.